Sec Form 3 Filing - Lunger John @ Adaptimmune Therapeutics PLC - 2019-08-01

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lunger John 2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ ADAP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Patient Supply Officer (Last) (First) (Middle) 216 WOODSTOCK ROAD 3. Date of Earliest Transaction (MM/DD/YY) 08/01/2019 (Street) VILLONOVA, PA19085 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares with a nominal value of GBP0.001 per share ( 1 ) 28,806 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Option to purchase Ordinary Shares $ 0.92 ( 3 ) ( 2 ) 04/03/2027 Ordinary Shares 250,032 D Option to purchase Ordinary Shares $ 0.81 ( 5 ) ( 4 ) 07/07/2027 Ordinary Shares 300,000 D Option to purchase Ordinary Shares $ 1.3 ( 7 ) ( 6 ) 01/12/2028 Ordinary Shares 100,800 D Option to purchase Ordinary Shares $ 0.0014 ( 10 ) ( 8 ) ( 9 ) Ordinary Shares 50,850 D Option to purchase Ordinary Shares $ 1.98 ( 12 ) ( 11 ) 07/02/2028 Ordinary Shares 181,872 D Option to purchase Ordinary Shares $ 0.0013 ( 15 ) ( 13 ) ( 14 ) Ordinary Shares 91,386 D Option to purchase Ordinary Shares $ 0.89 ( 17 ) ( 16 ) 01/04/2029 Ordinary Shares 100,800 D Option to purchase Ordinary Shares $ 0.0013 ( 20 ) ( 18 ) ( 19 ) Ordinary Shares 67,800 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lunger John 216 WOODSTOCK ROAD VILLONOVA, PA19085 Chief Patient Supply Officer Signatures /s/ John Lunger 08/05/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represented by 4,801 American Depositary Shares ("ADS") held by Mr. Lunger. Mr. Lunger holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. ( 2 )Exercisable as to 62,508 Ordinary Shares on April 3, 2018 and will be exercisable as to the remainder in monthly installments of 5,209 Ordinary Shares on the third of each month from May 3, 2018 through April 3, 2021. ( 3 )The exercise price was converted from GBP0.74 based on an exchange rate of U.S.$1.2493 to GBP1.00. The actual exercise price will be the pounds sterling amount. ( 4 )Exercisable as to 75,000 Ordinary Shares on July 7, 2018 and will be exercisable as to the remainder in monthly installments of 6,250 Ordinary Shares on the seventh of each month from August 7, 2018 through July 7, 2021. ( 5 )The exercise price was converted from GBP0.62 based on an exchange rate of U.S.$1.2949 to GBP1.00. The actual exercise price will be the pounds sterling amount. ( 6 )Exercisable as to 25,200 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 2,100 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022. ( 7 )The exercise price was converted from GBP0.96 based on an exchange rate of U.S.$1.3542 to GBP1.00. The actual exercise price will be the pounds sterling amount. ( 8 )Exercisable as to 16,950 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 16,950 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022. ( 9 )The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. ( 10 )The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.3542 to GBP1.00. The actual exercise price will be the pounds sterling amount. ( 11 )Exercisable as to 45,468 Ordinary Shares on July 2, 2019 and will be exercisable as to the remainder in monthly installments of 3,789 Ordinary Shares on the second of each month from August 2, 2019 through July 2, 2022. ( 12 )The exercise price was converted from GBP1.50 based on an exchange rate of U.S.$1.3196 to GBP1.00. The actual exercise price will be the pounds sterling amount. ( 13 )Exercisable as to 30,462 Ordinary Shares on July 2, 2019 and will be exercisable as to the remainder in annual installments of 30,462 Ordinary Shares on the second of each July from July 2, 2020 through July 2, 2022. ( 14 )The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. ( 15 )The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.3196 to GBP1.00. The actual exercise price will be the pounds sterling amount. ( 16 )Exercisable as to 25,200 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 2,100 Ordinary Shares on the fourth of each month from February 4, 2020 through Ja nuary 4, 2023. ( 17 )The exercise price was converted from GBP0.70. based on an exchange rate of U.S.$1.2633 to GBP1.00. The actual exercise price will be the pounds sterling amount. ( 18 )Exercisable as to 16,950 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 16,950 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023. ( 19 )The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. ( 20 )The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.2633 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.